Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes
- 30 October 2011
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 131 (2), 527-540
- https://doi.org/10.1007/s10549-011-1836-0
Abstract
Breast cancer screening programs make it possible to detect early cancer, thus reducing breast cancer mortality. We studied the clinicopathologic characteristics and prognosis of screen-detected invasive breast cancer compared with symptomatic breast cancer. And we compared the result according to molecular subtypes (luminal A, luminal B, Her2, and triple negative), with the goal of identifying the role of screening in each subtypes. From January 2002 to June 2008, 3,141 patients who underwent surgery for the treatment of invasive ductal carcinoma at Samsung Medical Center were included. Among them, 1,025 patients were screen-detected, and 2,116 patients who were screened over 2 years or never were symptomatic. We retrospectively reviewed the clinical and pathologic data. Screen-detected breast cancer was associated with older age, smaller tumor size, more hormone-receptor positive, less lymph node involvement, earlier stage, and reduced mortality compared with symptomatic breast cancer (P < 0.001). According to the molecular subtype, luminal A was most common (63.6%) and showed the most obvious survival benefit in screen-detected tumors in comparison with symptomatic tumors (5-year OS: 99.7 vs. 96.5%, 5-year DFS: 96.4 vs. 90.7%). Screen detection was independently associated with improved overall and disease-free survival outcomes after adjustment for covariates (HR 0.32, P = 0.035; HR 0.58, P = 0.020, respectively) only in the luminal A subtype. Differences in pathological features such as tumor size, nodal status, grade, and age at diagnosis with different molecular subtype distributions may explain the survival advantage of patients with screen-detected breast cancer. Screening programs seem to have a different efficacy depending on the molecular subtype of the breast cancer, especially in the luminal A subtype, for which screen detection acts as an independent prognostic factor itself.Keywords
This publication has 41 references indexed in Scilit:
- Independent Prognostic Value of Screen Detection in Invasive Breast CancerJNCI Journal of the National Cancer Institute, 2011
- Prognosis and pathology of screen‐detected carcinomasCancer, 2010
- Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survivalBritish Journal of Cancer, 2009
- Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort studyBreast Cancer Research, 2009
- Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of ScreeningClinical Cancer Research, 2008
- Pathologic findings from the Breast Cancer Surveillance ConsortiumCancer, 2006
- Effect of Screening and Adjuvant Therapy on Mortality from Breast CancerNew England Journal of Medicine, 2005
- Role of Detection Method in Predicting Breast Cancer Survival: Analysis of Randomized Screening TrialsJNCI Journal of the National Cancer Institute, 2005
- Risk for Distant Recurrence of Breast Cancer Detected by Mammography Screening or Other MethodsJAMA, 2004
- Breast cancers found by screening: earlier detection, lower malignant potential or both?Breast Cancer Research and Treatment, 2002